Start here if you're new
what it is
DiaMedica is developing DM199 for preeclampsia and acute ischemic stroke, plus DM300 for severe acute pancreatitis.
how it gets paid
Last year Diamedica Therap made n/a in revenue. DM199 for preeclampsia was the main engine at $0M, or 25% of sales.
what just happened
DiaMedica posted -$0.53 EPS in the latest quarter, and revenue was not reported.
At a glance
B balance sheet — gets the job done, barely
75/100 earnings predictability — reasonably predictable
-$0.60 fy2024 eps est
1.1 beta
~$379M market cap
xvary composite: 49/100 — below average
What they do
DiaMedica is developing DM199 for preeclampsia and acute ischemic stroke, plus DM300 for severe acute pancreatitis.
DM199 is the first pharmaceutically active recombinant form of KLK1 to be clinically studied in patients. That gives you one molecule with two shots at a big market, not five science projects. The balance sheet has $0M long-term debt, so the company is not paying a bank while it waits for data.
How they make money
n/a
annual revenue
DM199 for preeclampsia
$0M
DM199 for acute ischemic stroke
$0M
DM300 for severe acute pancreatitis
$0M
Corporate and research
$0M
The products that matter
clinical drug candidate
DM199 (recombinant KLK1)
$0 revenue · $379M equity story
it is the only meaningful asset in the current story. with no approved products, $0 revenue, and a $379M market cap, DM199 is not one contributor to value — it is the value investors are underwriting.
single asset
Key numbers
$379M
market cap
Market cap → market value of all shares → so what: you are paying $379M for a company with $0M trailing revenue.
$0M
long-term debt
Long-term debt → money owed after a year → so what: $0M means no lender is waiting in line.
1.1
beta
Beta → stock wobble versus the market → so what: 1.1 means a little more swing than average.
$8.53
share price
Share price → one share costs this much → so what: $8.53 makes every trial headline matter.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 3 — safer than 50% of stocks
- price stability 5 / 100
- long-term debt $0M (0% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for DMAC right now.
source: institutional data · return history unavailable
What just happened
missed estimates
DiaMedica posted -$0.53 EPS in the latest quarter, and revenue was not reported.
The company is still spending on clinical work. With $0M trailing revenue, the market is watching trial updates, not sales.
-$0.53
eps
n/a
n/a
n/a
n/a
the number that mattered
EPS of -$0.53 shows the company is still in the pre-revenue phase. That keeps the story tied to clinical data.
source: company quarterly filing, latest quarter
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is DM199 failing in acute ischemic stroke or preeclampsia. with $0 revenue and one lead asset, there is no second act if the data disappoints.
med
single-asset clinical failure
DM199 is the only meaningful value driver in the current story. If the readouts disappoint in stroke or preeclampsia, the equity thesis breaks with them.
This sits against a $379M market cap and $0 revenue. There is no operating business here to absorb a bad outcome.
med
cash burn and dilution
The company ended the quarter with $55.3M in cash and posted an $8.6M net loss in Q3 2025. If spending stays at that level and milestones slip, new capital moves from background risk to main event.
A financing round matters more in a company with only 10.12% institutional ownership and no revenue support. New shares would hit a small-cap name that already trades on belief.
med
trial timeline slippage
Health Canada clearance keeps the preeclampsia program alive, but clearance is not enrollment. Startup delays, slower patient recruitment, or protocol changes can still push proof further out.
Delay and failure are different, but they rhyme. One damages the science story. The other extends the period where cash leaves and evidence does not arrive.
With $0 revenue, a bad DM199 readout would pressure nearly all of the current $379M equity story. Delay would mainly drain the $55.3M cash balance and raise the odds that dilution gets there first.
source: institutional data · regulatory filings · risk analysis
Pay attention to
the key insight
cash has to outrun uncertainty
$55.3M in cash sounds fine until you pair it with $0 revenue and an $8.6M quarterly net loss. Your real question is whether proof shows up before financing does.
calendar
next earnings report is expected around March 17, 2026
For most companies, earnings are about sales and margins. Here, you are checking cash, loss rate, and whether management moved the DM199 timeline.
execution
Phase 2 preeclampsia study has clearance. now it needs motion.
Health Canada cleared the study on March 5, 2026. The next proof beat is not another announcement. It is actual trial execution in 2026.
risk
institutional sponsorship is still thin
Institutional ownership sits at 10.12%. If larger funds stay away, price moves can stay more sentiment-driven and less anchored by patient capital.
Analyst rankings
earnings predictability
75 / 100
losses have been relatively steady. in human-speak, nobody expects a surprise operating business to appear out of nowhere.
beta
1.1
beta measures market sensitivity. in plain english: DMAC has moved a bit more than the market, but the bigger swings usually come from trial headlines, not the index.
source: institutional data
Institutional activity
institutional ownership data for DMAC is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$9
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive